Log in

NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

$3.62
-0.38 (-9.50 %)
(As of 04/2/2020 08:36 AM ET)
Today's Range
$3.47
Now: $3.62
$4.21
50-Day Range
$3.12
MA: $5.52
$7.21
52-Week Range
$2.86
Now: $3.62
$16.05
Volume19,242 shs
Average Volume20,317 shs
Market Capitalization$17.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Read More
Alimera Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.94 million
Book Value($7.01) per share

Profitability

Net Income$-10,440,000.00

Miscellaneous

Employees124
Market Cap$17.99 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.


Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

How has Alimera Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALIM shares have decreased by 30.9% and is now trading at $3.62. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alimera Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alimera Sciences.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Alimera Sciences.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings data on Wednesday, February, 26th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.45. The biopharmaceutical company earned $17.35 million during the quarter, compared to analyst estimates of $14.50 million. View Alimera Sciences' earnings history.

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Alimera Sciences shares reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ALIM?

3 equities research analysts have issued 12 month price targets for Alimera Sciences' stock. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 728.7% from the stock's current price. View analysts' price targets for Alimera Sciences.

Has Alimera Sciences been receiving favorable news coverage?

News stories about ALIM stock have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alimera Sciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAlimera Sciences.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a increase in short interest in March. As of March 13th, there was short interest totaling 20,500 shares, an increase of 9.0% from the February 27th total of 18,800 shares. Based on an average trading volume of 45,300 shares, the short-interest ratio is currently 0.5 days. Approximately 0.5% of the shares of the company are short sold. View Alimera Sciences' Current Options Chain.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Opko Health (OPK), CorMedix (CRMD), Athersys (ATHX) and Gilead Sciences (GILD).

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
  • Dr. Kenneth Green, Consultant (Age 61)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 55)

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $3.62.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $17.99 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe. View additional information about Alimera Sciences.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is http://www.alimerasciences.com/.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel